EW
ALXN

Evoke Wealth’s Alexion Pharmaceuticals ALXN Stock Holding History

Evoke Wealth’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-88
Closed -$16K – 1247
2021
Q2 		$16K Sell
88
-4
-4% -$687 ﹤0.01% 689
2021
Q1 		$14K Hold
92
– – ﹤0.01% 642
2020
Q4 		$14K Buy
92
+4
+5% +$514 ﹤0.01% 538
2020
Q3 		$10K Hold
88
– – ﹤0.01% 571
2020
Q2 		$10K Sell
88
-8
-8% -$849 ﹤0.01% 557
2020
Q1 		$8.62K Sell
96
-46
-32% -$4.51K ﹤0.01% 524
2019
Q4 		$15.4K Buy
142
+38
+37% +$4.06K ﹤0.01% 652
2019
Q3 		$10.2K Buy
+104
New +$11.7K ﹤0.01% 815

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Evoke Wealth's ALXN Position: Q3 2021 in Review

Evoke Wealth sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 88 shares — an estimated $16K sold.

Evoke Wealth first reported a position in ALXN in Q3 2019 and held it in 8 quarters. The position peaked at $16K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Evoke Wealth reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Evoke Wealth sold 88 Alexion Pharmaceuticals shares in Q3 2021, an estimated $16K.
  • Evoke Wealth first reported a position in Alexion Pharmaceuticals in Q3 2019 and held it in 8 quarters.
  • Evoke Wealth's Alexion Pharmaceuticals position peaked at $16K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Evoke Wealth's 13F filing for Q3 2021, filed 12 Nov 2021.